Clinical Trial Update: Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing three biphasic insulin aspart formulations (70/30, 50/50, and 30/70) in adults with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoLog Mix 30/70 (insulin aspart protamine/insulin aspart 30/70)
• NovoLog Mix 50/50 (insulin aspart protamine/insulin aspart 50/50)
• NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart mix 70/30)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED